哥本哈根尿激酶型纤溶酶原激活物受体前列腺癌（CuPCa）数据库：方案与早期结果。
Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results.
作者信息
Lippert Solvej, Berg Kasper D, Høyer-Hansen Gunilla, Lund Ida K, Iversen Peter, Christensen Ib J, Brasso Klaus, Røder Martin A
机构信息
Copenhagen Prostate Cancer Center, Department of Urology, Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
The Finsen Laboratory, Rigshospitalet, Copenhagen, Denmark.
出版信息
Biomark Med. 2016;10(2):209-16. doi: 10.2217/bmm.15.114. Epub 2016 Jan 14.
AIM
Urokinase plasminogen activator receptor (uPAR) plays a central role during cancer invasion by facilitating pericellular proteolysis. We initiated the prospective 'Copenhagen uPAR Prostate Cancer' study to investigate the significance of uPAR levels in prostate cancer (PCa) patients.
METHODS
Plasma samples and clinical data from patients with newly diagnosed PCa have been collected prospectively. The uPAR forms have been measured in plasma using time-resolved fluorescence immunoassays.
RESULTS
The level of intact uPAR(I-III) did not differ. Plasma uPAR(I-III) + uPAR(II-III) levels and uPAR(I) levels were significantly higher in hormone-naive and castrate-resistant patients compared with patients with localized disease (both: p < 0.0001).
CONCLUSION
Our results show that cleaved uPAR forms are significantly increased in patients with advanced PCa.
目的
尿激酶型纤溶酶原激活物受体（uPAR）通过促进细胞周围蛋白水解在癌症侵袭过程中发挥核心作用。我们启动了前瞻性的“哥本哈根uPAR前列腺癌”研究，以调查uPAR水平在前列腺癌（PCa）患者中的意义。
方法
前瞻性收集新诊断PCa患者的血浆样本和临床数据。使用时间分辨荧光免疫分析法测定血浆中的uPAR形式。
结果
完整uPAR（I-III）的水平没有差异。与局限性疾病患者相比，激素初治和去势抵抗患者的血浆uPAR（I-III）+uPAR（II-III）水平和uPAR（I）水平显著更高（两者均为：p<0.0001）。
结论
我们的结果表明，晚期PCa患者中裂解的uPAR形式显著增加。
Zotero 插件